Related Experiment Video

Updated: Sep 20, 2026

Modeling Colitis-Associated Cancer with Azoxymethane (AOM) and Dextran Sulfate Sodium (DSS)
12:37

Modeling Colitis-Associated Cancer with Azoxymethane (AOM) and Dextran Sulfate Sodium (DSS)

Published on: September 11, 2012

Susceptibility to Ulcerative Colitis and Genetic Polymorphisms of A251G SOD1 and C-262T CAT

Gadier El-Kheshen1, Maryam Moeini2, Mostafa Saadat1

  • 1Department of Biology, College of Sciences, Shiraz University, Shiraz, Iran.

Journal of Medical Biochemistry
|March 31, 2017
PubMed
Abstract

Insights

The G allele of the superoxide dismutase 1 (SOD1) A251G polymorphism may protect against ulcerative colitis (UC). The catalase (CAT) C-262T polymorphism showed no association with UC risk in this study.

Area of Science:

  • Genetics and Molecular Biology
  • Gastroenterology
  • Oxidative Stress Research

Background:

  • Reactive oxygen species (ROS) can damage cellular components, necessitating robust antioxidant defenses.
  • Superoxide dismutase (SOD) and catalase (CAT) are key enzymes in combating ROS.
  • The role of ROS in ulcerative colitis (UC) pathogenesis is increasingly recognized.

Purpose of the Study:

  • To investigate the association between genetic polymorphisms in SOD1 (A251G) and CAT (C-262T) and the risk of developing UC.
  • To explore the potential protective role of antioxidant enzyme gene variants against UC.

Main Methods:

  • A case-control study involving 109 UC patients and 186 healthy controls.
  • Genotyping of SOD1 A251G (rs2070424) and CAT C-262T (rs1001179) polymorphisms using PCR-RFLP.
  • Statistical analysis adjusted for age and gender.

Main Results:

  • The AG+GG genotypes of the SOD1 A251G polymorphism were significantly associated with a decreased risk of UC (OR=0.29, P=0.025).
  • The G allele of SOD1 A251G was linked to a reduced risk of UC.
  • No significant association was found between the CAT C-262T polymorphism and UC risk.

Conclusions:

  • The G allele of the SOD1 A251G polymorphism appears to have a protective effect against ulcerative colitis.
  • These findings suggest a potential role for SOD1 genetic variants in UC susceptibility.
  • Further research is warranted to elucidate the precise mechanisms.
Keywords:
CATSOD1inflammatory bowel diseaseulcerative colitis

More Related Videos

Chronic Salmonella Infection Induced Intestinal Fibrosis08:40

Chronic Salmonella Infection Induced Intestinal Fibrosis

Published on: September 22, 2019

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform06:21

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform

Published on: May 10, 2024

Related Concept Videos

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters01:16

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters

The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Inflammatory Bowel Disease II: Ulcerative Colitis01:20

Inflammatory Bowel Disease II: Ulcerative Colitis

Ulcerative colitis is a chronic inflammatory disorder of the colon characterized by continuous mucosal inflammation that typically begins in the rectum and extends proximally in a uniform pattern. Its pathogenesis involves a complex interplay of genetic predisposition, immune dysregulation, and environmental influences. These factors converge to impair the colon’s epithelial defenses and promote an exaggerated inflammatory response against luminal contents.Breakdown of the Mucosal BarrierA...
Inflammatory Bowel Disease III: Crohn's Disease01:25

Inflammatory Bowel Disease III: Crohn's Disease

Crohn’s disease is a chronic, relapsing form of inflammatory bowel disease characterized by segmental, transmural inflammation that can affect any part of the gastrointestinal tract. Its pathogenesis arises from a combination of genetic susceptibility, environmental exposures, epithelial barrier dysfunction, and immune dysregulation. Together, these factors lead to an exaggerated immune response against components of the gut microbiome.Genetic and Environmental InfluencesMultiple genetic...